In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

DexCom (NASDAQ:DXCM – Get Free Report) had its target price increased by stock analysts at Canaccord Genuity Group from $89.00 to $99.00 in a research report issued to clients and investors on Monday, ...

DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors ...

Tandem Diabetes Care announced today that t:slim X2 insulin pump users in Canada can now access full compatibility with ...

DexCom Inc (NASDAQ:DXCM) shares up more than 2% following updated guidelines by the American Diabetes Association (ADA), which now recommend using continuous glucose monitors (CGMs) for some adults ...

The American Diabetes Association has released its annual guidelines and they now include continuous glucose monitor use for non-insulin use, ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...

DexCom, Inc. (DXCM), headquartered in California, is a leading player in the medical devices sector. Valued at a market cap ...

The BNY Mellon Small/Mid Cap Growth Fund (Class A at NAV) returned 3.05% during the third quarter of 2024. Read more here.

In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a ...

The latest addition to the pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy. The company’s extended wear infusion set technology ...